It has been well documented that activation of HER2, as exemplified by gene amplification, is a major driving force for the development of breast cancer, lung cancer, colorectal cancer, gastric cancer, ovarian cancer and uterine cancer. This evidence concerns the gene ERBB2 and ovarian carcinoma.